Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 12/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 6/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD5 | P21918 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | PER2 | O15055 | 1/20 | 0.46 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696116 | 0.85 | HTR7 (0.57) | HTR7NOTUMHTR1ADRD2DRD5 | |
| SCHEMBL30460612 | 0.83 | POLB (0.65) | DRD2DRD3DRD4POLB | |
| SCHEMBL6656950 | 0.83 | POLB (0.65) | DRD2DRD3DRD4POLB | |
| SCHEMBL30382092 | 0.81 | HTR7 (0.53) | HTR7NOTUMHTR1APRMT5WDR77 | |
| SCHEMBL27451951 | 0.81 | HTR7 (0.53) | HTR7NOTUMHTR1APRMT5WDR77 | |
| SCHEMBL5113192 | 0.81 | HTR7 (0.53) | HTR7NOTUMHTR1APRMT5WDR77 | |
| SCHEMBL28279911 | 0.81 | HTR7 (0.53) | HTR7NOTUMHTR1APRMT5WDR77 | |
| SCHEMBL5394439 | 0.81 | HTR7 (0.53) | HTR7NOTUMHTR1APRMT5WDR77 | |
| SCHEMBL5966716 | 0.80 | MEN1 (0.52) | HTR7NOTUMHTR1APRMT5WDR77 | |
| SCHEMBL29963849 | 0.80 | MEN1 (0.52) | HTR7NOTUMHTR1APRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1906160-A | Imidazole derivatives, processes for preparing them and their uses | UCB SA (BE) | 2007-01-31 | — | — | CN | claimed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | claimed |
| CN-112159344-B | Synthesis method of 1, 3-dimethyl-3-hydroxymethyl indoline-2-ketone compound | 湖南科技学院 | 2021-11-09 | — | — | CN | disclosed |
| CN-112159344-A | Synthesis method of 1, 3-dimethyl-3-hydroxymethyl indoline-2-ketone compound | 湖南科技学院 | 2021-01-01 | — | — | CN | disclosed |
| CN-102753556-B | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC | 2015-05-13 | — | — | CN | disclosed |
| CN-102256983-A | Spirooxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2011-11-23 | — | — | CN | disclosed |
| US-7763644-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-7763644-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-7763644-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| EP-2050736-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2050736-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. | 2008-04-03 | — | — | US | disclosed |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. | 2008-04-03 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| CN-1906160-A | Imidazole derivatives, processes for preparing them and their uses | UCB SA (BE) | 2007-01-31 | — | — | CN | disclosed |
| EP-1706376-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | disclosed |
| WO-2005054188-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | HTR7 404/4885NOTUM 2112/4885HTR1A 1204/4885 |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | HTR7 404/4885NOTUM 2112/4885HTR1A 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.